Sections
Title | Starting Page | Number of Pages |
---|
Table of Contents | 2 | 6 |
List of Tables | 6 | 1 |
List of Figures | 7 | 1 |
Introduction | 8 | 1 |
Global Markets Direct Report Coverage | 8 | 1 |
Vancomycin-Resistant Enterococcus faecium Infections Overview | 9 | 1 |
Therapeutics Development | 10 | 2 |
Pipeline Products for Vancomycin-Resistant Enterococcus faecium Infections Overview | 10 | 1 |
Pipeline Products for Vancomycin-Resistant Enterococcus faecium Infections Comparative Analysis | 11 | 1 |
Vancomycin-Resistant Enterococcus faecium Infections Therapeutics under Development by Companies | 12 | 2 |
Vancomycin-Resistant Enterococcus faecium Infections Therapeutics under Investigation by Universities/Institutes | 14 | 1 |
Vancomycin-Resistant Enterococcus faecium Infections Pipeline Products Glance | 15 | 2 |
Clinical Stage Products | 15 | 1 |
Early Stage Products | 16 | 1 |
Vancomycin-Resistant Enterococcus faecium Infections Products under Development by Companies | 17 | 2 |
Vancomycin-Resistant Enterococcus faecium Infections Products under Investigation by Universities/Institutes | 19 | 1 |
Vancomycin-Resistant Enterococcus faecium Infections Companies Involved in Therapeutics Development | 20 | 18 |
Alchemia Limited | 20 | 1 |
Alvogen Korea Co., Ltd. | 21 | 1 |
Aphios Corporation | 22 | 1 |
C3 Jian, Inc | 23 | 1 |
Cellceutix Corporation | 24 | 1 |
Helix BioMedix, Inc. | 25 | 1 |
Hsiri Therapeutics LLC | 26 | 1 |
LegoChem Biosciences, Inc | 27 | 1 |
Lytix Biopharma AS | 28 | 1 |
MGB Biopharma Limited | 29 | 1 |
MicuRx Pharmaceuticals, Inc. | 30 | 1 |
Nanotherapeutics, Inc. | 31 | 1 |
NovoBiotic Pharmaceuticals, LLC | 32 | 1 |
Oragenics, Inc. | 33 | 1 |
Sealife PHARMA GMBH | 34 | 1 |
Sentinella Pharmaceuticals, Inc. | 35 | 1 |
TAXIS Pharmaceuticals, Inc. | 36 | 1 |
Wockhardt Limited | 37 | 1 |
Vancomycin-Resistant Enterococcus faecium Infections Therapeutics Assessment | 38 | 9 |
Assessment by Monotherapy Products | 38 | 1 |
Assessment by Target | 39 | 2 |
Assessment by Mechanism of Action | 41 | 2 |
Assessment by Route of Administration | 43 | 2 |
Assessment by Molecule Type | 45 | 2 |
Drug Profiles | 47 | 48 |
AM-218 Drug Profile | 47 | 1 |
BDM-I Drug Profile | 48 | 2 |
brilacidin tetrahydrochloride Drug Profile | 50 | 10 |
chrysophaentin Drug Profile | 60 | 1 |
closthioamide Drug Profile | 61 | 1 |
Epimerox Drug Profile | 62 | 1 |
HB-1345 Drug Profile | 63 | 1 |
HT-01 Drug Profile | 64 | 1 |
HT-02 Drug Profile | 65 | 1 |
IBN-1 Drug Profile | 66 | 1 |
LCB-010371 Drug Profile | 67 | 2 |
LCB-010699 Drug Profile | 69 | 1 |
LTX-109 Drug Profile | 70 | 2 |
Marinus Drug Profile | 72 | 1 |
MGBBP-3 Drug Profile | 73 | 2 |
MRX-I Drug Profile | 75 | 2 |
MRX-IV Drug Profile | 77 | 1 |
NAI-107 Drug Profile | 78 | 1 |
NAI-108 Drug Profile | 79 | 1 |
NAI-603 Drug Profile | 80 | 1 |
OG-253 Drug Profile | 81 | 2 |
ramoplanin Drug Profile | 83 | 1 |
SLP-0904 Drug Profile | 84 | 1 |
SLP-0905 Drug Profile | 85 | 1 |
Small Molecules for Bacterial Infections Drug Profile | 86 | 1 |
Small Molecules to Inhibit FtsZ Protein for MRSA and VRE Infections Drug Profile | 87 | 1 |
Small Molecules to Inhibit Glycosyltransferase for Bacterial Infections Drug Profile | 88 | 1 |
Small Molecules to Inhibit Oxacillinase for Gram-Positive Bacterial Infections Drug Profile | 89 | 1 |
SP-2078 Drug Profile | 90 | 1 |
Synthetic Peptides for Vancomycin Resistant Enterococci Infections Drug Profile | 91 | 1 |
Teixobactin Drug Profile | 92 | 2 |
WCK-4086 Drug Profile | 94 | 1 |
Vancomycin-Resistant Enterococcus faecium Infections Dormant Projects | 95 | 1 |
Vancomycin-Resistant Enterococcus faecium Infections Discontinued Products | 96 | 1 |
Vancomycin-Resistant Enterococcus faecium Infections Product Development Milestones | 97 | 3 |
Featured News &Press Releases | 97 | 1 |
Feb 25, 2015: MicuRx Initiates U.S. Phase 2 Clinical Trial For Novel Antibiotic MRX-I | 97 | 1 |
Aug 26, 2013: Oragenics Collaboration Demonstrates Initial Success in the Second Phase of Lantibiotics Project | 97 | 1 |
Feb 12, 2013: Oragenics-Intrexon Collaboration Announces Significant Progress Towards Commercial Production of Lead Lantibiotic MU1140 | 98 | 1 |
May 23, 2012: MicuRx Announces Issuance Of US Patent For Next-Generation Antibacterial Agent | 98 | 1 |
Apr 23, 2012: MicuRx Completes Phase I Trial For MRX-I | 99 | 1 |
Appendix | 100 | 2 |
Methodology | 100 | 1 |
Coverage | 100 | 1 |
Secondary Research | 100 | 1 |
Primary Research | 100 | 1 |
Expert Panel Validation | 100 | 1 |
Contact Us | 100 | 1 |
Disclaimer | 101 | 1 |